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The epiphyseal growth plate consists of a layer of cartilage present only during the growth
period and vanishes soon after puberty in long bones. It is divided to three well-deﬁned
zones, from epiphyses; resting, proliferative, and hypertrophic zones. Chondrocyte prolifer-
ation and differentiation and subsequent bone formation in this cartilage are controlled by
various endocrine, autocrine, and paracrine factors which ﬁnally results into elimination of
the cartilaginous tissue and promotion of the epiphyseal fusion. As chondrocytes differen-
tiate from round, quiescent, and single structure to ﬂatten and proliferative and then large
and terminally differentiated, they experience changes in their gene expression pattern
which allow them to transform from cartilaginous tissue to bone. This review summarizes
the literature in this area and shortly describes different factors that affect growth plate
cartilage both at the local and systemic levels. This may eventually help us to develop new
treatment strategies of different growth disorders.
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INTRODUCTION
The bone and cartilage tissues of our skeletal system provide both
mechanical support and protection of the vital organs of the
body, including the heart, lungs, and brain. Consequently, nor-
mal growth and development of skeletal bone is essential. These
processes involve two distinct pathways:membranous ossiﬁcation,
which gives rise to calvarial bones directly from osteoblastic cells;
and endochondral ossiﬁcation. The latter, is an important process
in the replacement of the fetal skeleton during organogenesis and
bone elongation until adult height is achieved.
Bone elongation occurs through proliferation and differentia-
tion of the cells located in the cartilage of the epiphyseal growth
plates at the ends of the long bones. These plates are present only
during the growth period and vanish when sexual maturation is
complete.
The growth plate is divided into three well-deﬁned zones. Clos-
est to the epiphysis, the resting zone (also known as the germinal
zone) contains single or pairs of small, uniformly round, and
relatively quiescent cells embedded in a large volume of extra-
cellular matrix (ECM; Ballock and O’Keefe, 2003; Melrose et al.,
2008). Immediately beneath this zone lies the proliferative zone,
where the chondrocytes ﬂatten, begin to divide and form ladders
parallel to the bone alignment, and synthesize collagen of types
II and XI (Ballock and O’Keefe, 2003). In the underlying zone
of maturation, referred to as the hypertrophic zone, the chon-
drocytes which are larger and more swollen than in the other
zones, begin their terminal differentiation. The characteristic fea-
tures of these hypertrophic chondrocytes include a lack of cell
division, a pronounced increase in alkaline phosphatase activ-
ity and synthesis of large amounts of various elements of the
ECM, including type-X collagen, a unique short-chain collagen
found only in this zone (O’Keefe et al., 1994; Karimian et al.,
2008). This morphological transformation is regulated by various
hormones and growth factors, both at systemic and local levels
(Figure 1).
LOCAL REGULATION OF THE GROWTH PLATE
The key para/autocrine regulators of bone formation are bone
morphogenic proteins (BMPs), ﬁbroblast growth factors (FGFs),
hedgehog proteins and parathyroid hormone-related peptide
(PTHrP), C-type natriuretic peptide (CNP), vascularization fac-
tors and vitamin D, transforming growth factor beta (TGF-β),
CCAART/enhancing binding protein beta (C/EBP beta), pannexin
3, cilia and glycosylphosphatidylinositol (GPI).
BONE MORPHOGENIC PROTEINS
Bone morphogenic proteins are growth and differentiation factors
which have pivotal roles at every stage of endochondral bone for-
mation and angiogenesis (Moser and Patterson, 2005; Zhang et al.,
2009). Lack of BMPs and/or their receptors results into failure in
mesenchymal condensation or digit formation in mice (Storm
and Kingsley, 1999; Baur et al., 2000; Pizette and Niswander,
2000). At later stages, these proteins are expressed in the peri-
chondriumaswell as hypertrophic and proliferative chondrocytes.
Indian hedgehog (Ihh) expression in prehypertrophic chondro-
cytes increases through BMP signaling (Minina et al., 2001, 2002),
thereby increasing both the rate of chondrocyte proliferation and
the length of proliferative columns. Furthermore, in vitro these
factors directly trigger chondrogenesis by human mesenchymal
stem cells to induce the formation of hypertrophic chondrocytes
(Steinert et al., 2009).
FIBROBLAST GROWTH FACTORS
Genetic studies have shown that FGF-signaling play a key role in
regulating chondrogenesis and 22 different FGFs and four target
receptor (FGFR) genes are expressed at every stage of endochon-
dral ossiﬁcation (Ornitz and Marie, 2002; Ornitz, 2005). FGFs
acting via FGF receptor-3 (FGFR3) are the key negative regula-
tors in chondrocyte proliferation. An activation mutation in this
receptor inhibits linear bone growth and may cause achondropla-
sia, hypochondroplasia, or type I or II thanatophoric dysplasia
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FIGURE 1 | Schematic picture of growth plate cartilage. At different stages in their development growth plate chondrocytes exhibit different pattern of gene
expression.
(Horton et al., 2007). In human growth plate cartilage pre-
dominant FGF ligands are FGF 1, 2, 17, and 19 (Krejci et al.,
2007). All FGF ligands have the potential to bind FGFR3 as
demonstrated in experimental studies (Ornitz et al., 1996; Zhang
et al., 2006; Krejci et al., 2007). Inhibition of proliferation by
FGF-signaling through FGFR3 involves, at least partially, activa-
tion of Janus kinase signaling and activator of transcription-1
(JAK–STAT1; Colvin et al., 1996). The expression of FGFs and
their receptors in postnatal growth plate cartilage suggests that
these proteins contribute to growth plate senescence and thus
help to determine the size of the adult skeleton (Lazarus et al.,
2007).
SIGNALING BY INDIAN HEDGEHOG/PARATHYROID HORMONE-RELATED
PROTEIN
Indian hedgehog, the key paracrine regulator of bone devel-
opment, orchestrates chondrocyte proliferation, and differenti-
ation, as well as osteoblast differentiation. During bone forma-
tion, Ihh is expressed and secreted by post-mitotic hypertrophic
chondrocytes simultaneously with expression of the parathyroid
hormone-related protein receptor (PPR; Figure 1). Ihh diffuses
throughout the growth plate and binds to its receptor, Patched-
1 (Ptc-1) expressed by chondrocytes in the resting zone. This, in
turn, activates downstream signaling via Smoothened (Smo) and
transcription factors of the Gli family and leads to elevation of
PTHrP expression (St-Jacques et al., 1999). PTHrP is expressed
by periarticular chondrocytes, diffuses throughout the growth
plate and delays differentiation of columnar chondrocytes into
hypertrophic, thereby increasing the distance between the Ihh-
expressing domain and the Ihh-targeted cell population. Thereby
the Ihh/PTHrP feedback loop is formed which controls fetal
growth plate development (Kronenberg, 2003).
The importance of the Ihh/PTHrP feedback loop for postnatal
growth was recently revealed. Inactivation of either Ihh or PPR
in postnatal chondrocytes leads to abrupt fusion of the epiphyseal
growth plate in mice (Maeda et al., 2007; Hirai et al., 2011), thus
suggesting that the loop is crucial for maintaining the growth plate
in the open phase.
The importance of the Ihh/PTHrP loop for human physiology
is exempliﬁed by the following observations. Both Ihh and PTHrP
are expressed in the human growth plate and expression levels
correlate with pubertal progression (Kindblom et al., 2002). Inac-
tivating mutation in Ihh results in acrocapitofemoral dysplasia,
which is associated with premature closure of the growth plates
(Hellemans et al., 2003). Inactivatingmutation in the PTH/PTHrP
receptor results in Blomstrand dysplasia (Jobert et al., 1998; Kara-
plis et al., 1998; Zhang et al., 1998). Patients with Blomstrand dys-
plasia die in uterus, but their skeletal abnormalities closely resem-
bling those of the PTH/PTHrP receptor deﬁcient mice (Lanske
et al., 1996; Karaplis et al., 1998; Zhang et al., 1998). Further-
more, humans with Jansen chondro-osteodystrophy have point
mutations in the gene encoding the PTH/PTHrP receptor that
render the receptor active even in the absence of ligand (Schipani
et al., 1995, 1996). Such people have growth abnormalities due to
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delay in hypertrophic chondrocyte differentiation and resultant
short stature. Recently, two reports of families with inactivating,
heterozygous mutations of the PTHrP gene show that such het-
erozygosity for PTHrP causes brachydactyly type E associatedwith
premature cessation of growth in many cases (Klopocki et al.,
2010; Maass et al., 2010). Finally, loss-of-function mutation in
the GNAS1 gene, which encodes the α-subunit of the stimulatory
G-protein (Gsα), downstream mediator of PPR in chondrocytes
(Bastepe et al., 2004), leads to Albright hereditary osteodystrophy
(AHO), which often display brachydactyly and premature closure
of the epiphyseal growth plate (Steinbach and Young, 1966; Poz-
nanski et al., 1977; Graudal et al., 1986). Altogether, existing data
suggest that both in mice and humans the Ihh/PTHrP loop is
crucial for maintaining the growth plate in an open phase.
C-TYPE NATRIURETIC PEPTIDE
C-type natriuretic peptide is a member of the natriuretic peptide
family, together withANP and BNP proteins (Rosenzweig and Sei-
dman, 1991), and it is widely expressed in many tissues including
growth plate cartilages (Hagiwara et al., 1994). It has been identi-
ﬁed as a crucial regulator of endochondral bone growth (Chusho
et al., 2001; Olney, 2006). CNP promotes chondrogenesis by stim-
ulating expression of molecules involved in cell adhesion and
glycosaminoglycan synthesis (Woods et al., 2007). It acts through
natriuretic peptide receptor 2 (NPr2). Disruption of the genes
encoding CNP or NPr2 results into dwarﬁsm and impaired endo-
chondral ossiﬁcation (Komatsu et al., 2002; Tamura et al., 2004)
in mice.
VASCULARIZATION FACTORS
During limb bud development, chondrocytes in the middle of the
bud undergo hypertrophic differentiation. Hypertrophic chon-
drocytes express several chemoattractant proteins, including vas-
cular endothelial growth factor (VEGF; Zelzer et al., 2001), high
mobility group box 1 protein (HMG-1; Taniguchi et al., 2007),
and receptor activator of NFκB ligand (RANK-L; Kishimoto et al.,
2006). This, in turn, attracts blood vessel invasion and brings in
endothelial cells, osteoclasts, and osteoblasts leading to formation
of the primary ossiﬁcation center and bone development.
During bone elongation, vascularization is also of extreme
importance. Despite the growth plate is an avascular structure,
vascularization is important for substitution of cartilage tissue by
bone tissue during endochondral ossiﬁcation. Indeed, inactivating
VEGF in mice utilizing soluble VEGF receptor impairs cartilage
resorption leading to expansion of the hypertrophic zone and
impaired formation of trabecular bone (Gerber et al., 1999). In
addition, conditional inactivation of the Vegfa gene in the mouse
growth plate leads to delayed invasion of blood vessels into the
primaryossiﬁcation center anddelayed removal of terminal hyper-
trophic chondrocytes together with massive cell death in chondro-
cytes throughout the growth plate (Zelzer et al., 2004). Interest-
ingly, estrogens can modulate the amount of VEGF expressed by
growth plate chondrocytes, thus providing a new plausible mecha-
nism for estrogen-dependent bone formation (Emons et al., 2010).
Supporting such a mechanism is the fact that mice overexpressing
VEGF in the growth plate dramatically increase their trabecular
bone mass whereas the growth plate itself is not affected (Maes
et al., 2010). Thus, vascularization is unequivocally important
for bone elongation and new bone formation. However, if this
process is utilized by the endocrine system to modulate fusion of
the growth plate remains to be elucidated.
VITAMIN D
Vitamin D needs double hydroxylation, 1α, 25-(OH)2D3, to exert
its biological activity (DeLuca, 2004). Vitamin D deﬁciency results
in rickets with disorganized growth plate, impaired mineraliza-
tion, and widening of the growth plate. 1α, 25-(OH)2D3, locally
regulates the growth plate cartilage,partially through amechanism
which involves the nuclear vitamin D receptor (Boyan et al., 2003).
Less differentiated chondrocytes, including those in the resting
zone, respond to 24,25-(OH)2D3 (Boyan et al., 2002, 2003; Deni-
son et al., 2009) whereas more differentiated cells, including pre-
hypertrophic and hypertrophic chondrocytes, respond primarily
to 1α, 25-(OH)2D3 (Boyan et al., 2003). It has been reported that
vitamin D receptor knockout mice (VDR−/−) arrests longitudi-
nal bone growth 5weeks after birth and peripheral quantitative
computed tomography analysis of the femur midshaft show a sig-
niﬁcant decrease in all bone parameters (Xue and Fleet, 2009)
when compared to the control mice. Disorganized, widened, and
expanded growth plates in VDR−/−mice indicate the important
role of vitamin D on longitudinal bone growth (Xue and Fleet,
2009).
TRANSFORMING GROWTH FACTOR BETA
The signiﬁcance of TGF-β during skeletal development has been
well established in different species (Gatherer et al., 1990; Pelton
et al., 1990). It has been shown that a mutation in a TGF-β super-
family member causes skeletal dysplasia (Thomas et al., 1996).
Recently it has been shown that E-selectin ligand-1 regulates
growth plate homeostasis in mice by inhibiting the intracellular
processing and secretion of mature TGF-β and therefore prevents
skeletal dysplasia (Yang et al., 2010). In addition TGF-β is involved
in biomineralization through ankyrin, an important inorganic
pyrophosphate transporter (Skubutyte et al., 2010).
CCAART/ENHANCING BINDING PROTEIN BETA AND PANNEXIN 3
Transition of the chondrocytes from resting to proliferative and
from proliferative to hypertrophic phase is a crucial step for endo-
chondral ossiﬁcation. The transcription factor (C/EBP beta) pro-
motes the transition of proliferative chondrocytes to hypertrophic
chondrocytes through transactivation of p57 (Hirata et al., 2009).
Pannexin 3, amember of the gap junctionprotein family,promotes
chondrocytes differentiation from proliferative to hypertrophic
by regulating the intracellular ATP/cAMP levels (Iwamoto et al.,
2010).
CILIA AND GLYCOSYLPHOSPHATIDYLINOSITOL (GPI)
The primary cilia may be partially responsible for polariza-
tion gradients in the growth plate allowing ladder alignment
of chondrocytes in the proliferative zone. In addition, primary
cilia might be important for transducing Ihh signaling (Koyama
et al., 2007). Glycosylphosphatidylinositol (GPI) presumably con-
tributes to this process via cell signaling and adhesion (Ahrens
et al., 2009).
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SYSTEMIC REGULATION OF THE GROWTH PLATE
During childhood longitudinal bone growth is regulated by a
number of key hormones including growth hormone (GH),
insulin-like growth factor-I (IGF-I), glucocorticoids, and thyroid
hormone. During sexual maturation sex steroids (androgens and
estrogens) contribute signiﬁcantly to this process.
THE GH/IGF-I SYSTEM
From the second trimester of gestation GH is synthesized by the
anterior pituitary gland (Kaplan et al., 1972). The physiological
role of GH during fetal life is not well understood. During fetal
life, IGF-I and IGF-II are generally believed to be the key determi-
nants of embryonic growth (Honnebier and Swaab, 1973; Woods
et al., 1996) although a later report indicated that GH may inﬂu-
ence fetal development (Waters and Kaye, 2002). On the other
hand, following birth and throughout puberty and adulthood GH
is well known to play a critical role for longitudinal bone growth
(Isaksson et al., 1987; Guler et al., 1988; van der Eerden et al.,
2003), exerting anabolic effects on both trabecular and cortical
bone (Giustina et al., 2008).
Growth hormone exerts its effects directly by binding to
a single-chain trans-membrane glycoprotein receptor (GHR)
expressed at high levels in almost all organs including growth plate
cartilage (Gevers et al., 2002).At the same time, this hormone stim-
ulates the production of IGF-I (formerly known as somatomedin
C) in the liver (Melmed, 1999), which is the major target organ for
GH and the principal site of IGF-I production. Also, several extra-
hepatic tissues synthesize this hormone under the local control of
various hormones including GH (Ohlsson et al., 2009).
Ninety-nine percent of all circulating IGF-I is part of a 150-kD
ternary complex also containing its dominant circulatory binding
proteins, IGFBP-3 or IGFBP-5, and the acid labile subunit (ALS;
Boisclair et al., 2001). This ternary complex stabilizes IGF-I, pro-
longing its half-life and availability to target organs (Boisclair et al.,
2001). Genetic ablation of individual components of this complex
(i.e., liver-speciﬁc IGF-I,ALS, and IGFBP-3) only partially reduces
serum levels of IGF-I and yields only minor skeletal abnormalities,
indicating that the remaining serum IGF-I still exerts a substantial
impact on the skeleton (Yakar et al., 2009), alternatively, that an ele-
vation in the level of GH is sufﬁcient to compensate for the defect.
However, triple-knockout mice lacking liver-speciﬁc IGF-1, ALS,
and IGFBP-3 exhibit a 97% reduction in their serum level of IGF-I
and obvious destruction of bone (Yakar et al., 2009). At the same
time, this destruction was markedly less severe than in IGF-I-null
mice (Liu et al., 1993), strongly suggesting that local IGF-I and its
complexes in tissues, rather than circulating IGF-I, play a major
role in skeletal development. Interestingly, a more recent study by
Stratikopoulos et al. (2008) showed that mice expressing IGF-I in
their livers only attain no more than approximately 30% of the
normal adult body size during postnatal development, i.e., that
endocrine IGF-I plays a highly signiﬁcant role in murine growth.
GLUCOCORTICOIDS
Glucocorticoid (GC) therapies often impair growth in both
humans and animals (Altman et al., 1992; Allen, 1996; Chrysis
et al., 2003), while hereditary deﬁciencies in these steroids are
associated with tall stature (Elias et al., 2000). In rats and humans,
epiphyseal cartilage and bone cells express the GC receptor (Sil-
vestrini et al., 1999; Abu et al., 2000) suggesting that GCs exert
direct effects on these tissues.
Even low doses of GCs suppress bone growth in both humans
and animals, an effect believed to bemediated throughdisturbance
of the GH/IGF-I axis at different levels (Allen, 1996; Smink et al.,
2003). Smink et al. (2003) showed that such short-term treatment
of mice inhibits growth signiﬁcantly, decreases the width of the
growth plate and the rate of chondrocyte proliferation, promotes
apoptosis in hypertrophic chondrocytes, and reduces the local level
of IGF-I in the growth plate. Baron et al. (1992) found that local
infusion of dexamethasone into the epiphyseal growth plate of one
leg of rabbits inhibits the growth of this leg and following dex-
amethasone withdrawal, catch-up growth in comparison to the
contralateral leg occurs. Furthermore, we have recently demon-
strated that both dexamethasone-dependent growth inhibition as
well as followed catch-up growth occurs in cultured rat metatarsal
bones (Chagin et al., 2010). These observations suggest that both
the inhibitory effects of GCs on growth, as well as catch-up growth
following GC withdrawal are characteristic of the growth plate,
even though alterations in the GH/IGF system also play a role in
this connection.
THYROID HORMONES
Thyroid hormones are important positive regulators of chondro-
cyte proliferation and hypertrophy (Shao et al., 2006;Mackie et al.,
2011). In humans, hypothyroidism leads to retardation of longi-
tudinal bone growth (Rivkees et al., 1988). In vitro studies have
demonstrated that triiodothyronine (T3) stimulates chondrocytes
hypertrophy together with molecular markers of differentiated
chondrocytes (Burch and Lebovitz, 1982; Bohme et al., 1992;Wang
et al., 2007). Mice lacking thyroid hormone receptor alfa-1 mani-
fest typical features of skeletal hypothyroidism, postnatal growth
retardation, and delayed endochondral ossiﬁcation (O’Shea et al.,
2005).
ANDROGENS
Androgens are important for male gonadal differentiation dur-
ing fetal life, for sexual maturation and maintenance during and
after puberty as well as genital function and spermatogenesis
during adulthood. However, their impact on bone growth and
development in men remains not fully understood.
The androgen receptor (AR) is widely expressed in growth plate
cartilage of several species, including rat, rabbit, and human (Abu
et al., 1997; Ben-Hur et al., 1997; Nilsson et al., 2003a). Unilateral
injection of testosterone into the epiphyseal growth plate of the rat
tibia expands the width of this growth plate in comparison to the
contralateral one (Ren et al., 1989). Moreover, non-aromatizable
androgens such as dihydrotestosterone (DHT) and oxandrolone
accelerate the rate of bone growth in patients without affecting
systemic levels of GH (Stanhope et al., 1988; Veldhuis et al., 1997).
In girls with Turner syndrome,oxandrolone has been used in com-
bination with GH therapy and has been shown to increase both
growth rate and adult height when given alone or in combina-
tion with GH (Batch, 2002). All mentioned evidences suggest that
androgens have the capacity to stimulate bone growth, an effect
which could be systemically and/or locallymediated.Oxandrolone
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has been found not to inﬂuence the growth of cultured fetal rat
metatarsal bones suggesting that androgens in vivo might stim-
ulate longitudinal bone growth by acting indirectly, rather than
directly on growth plate chondrocytes (Chagin et al., 2009). Inter-
estingly,Sun et al. (2011) recently reported that dehydroepiandros-
terone (DHEA) suppresses the growth of cultured metatarsal
bones by acting directly at the growth plate level through estrogen
receptor (ER) interaction. This effect is however not surprising as
DHEA is easily aromatized to estrogens, a processwhichmay occur
locally in the growth plate where the P450 aromatase (CYP19) is
known to be expressed (Oz et al., 2001).
The evidence accumulated so far suggests that testosterone
affects bone growth only after being, locally in the growth plate,
aromatized to estrogens. Furthermore,despite demonstrating nor-
mal levels of testosterone both aromatase-deﬁcient males and
females exhibit the characteristic features of estrogen deﬁciency,
i.e., an unfused epiphysis, markedly delayed bone development
and severe osteopenia in adulthood (Morishima et al., 1995;Carani
et al., 1997). Together, these ﬁndings indicate that estrogens should
not be considered tobe solely female hormones,butmore generally
as sex steroids required for normal bone growth and development
in both females and males.
ESTROGENS AND THE ESTROGEN RECEPTORS
Estrogens inﬂuence target organs through two known nuclear
receptors, estrogen receptor-α (ERα; Green et al., 1986; Greene
et al., 1986) and estrogen receptor-β (ERβ; Kuiper et al., 1996;
Figure 2). These two receptors considered as classical ligand-
activated transcription factors, located in the cytosol until binding
their ligand. Then estrogen–ER complexes are translocated into
thenucleus and interactwith estrogen response elements (EREs) in
the promoter regions of target genes. Additionally, estrogens bind
to subpopulations of ERα and ERβ associated with the plasma
membrane, thereby rapidly activating a variety of intracellular
signaling cascades.
More recently, a membranous G-protein-coupled estrogen
receptor (GPER; formerly named GPR30) that rapidly mediates
estrogen signaling was discovered (Revankar et al., 2005). This
receptor is widely expressed in the hypertrophic zone of human
growth plate cartilage and the expression level decreases dur-
ing pubertal progression, suggesting that GPER is involved in
modulating longitudinal bone growth (Chagin and Sävendahl,
2007). Indeed, in vivo studies using genetically modiﬁed mice with
targeted deletion of this receptor showed that GPER is required for
normal estrogenic responses in the growth plate (Windahl et al.,
2009).
ENDOGENOUS PRODUCTION OF ESTROGEN
Based on numerous in vivo and in vitro studies, it is now well
established that chondrocytes can produce estrogens (Oz et al.,
2001; Sylvia et al., 2002; van der Eerden et al., 2002). Expression of
P450 aromatase in growthplate cartilage of bothhumans (Oz et al.,
2001) and rats (van der Eerden et al., 2002; Chagin et al., 2006) fur-
ther supports that chondrocytes have the potential to synthesize
this hormone. Furthermore, local production of estrogens have
been reported to be of importance for chondrocyte proliferation,
protecting these cells from spontaneous cell death, and thereby
regulating longitudinal bone growth (Chagin et al., 2006).
ROLE OF ESTROGENS ON BONE MATURATION AND GROWTH PLATE
FUSION
Estrogens were ﬁrst considered as female hormones primarily
responsible for pubertal growth and sexual organ development
in girls, acting similarly as androgens do in boys. This theory
was challenged by Smith and his colleagues in the 1990s when
they described a unique case of an extremely tall 28-year-old
man who still had unfused epiphyses, a bone age of 15 years,
and a lumbar spine BMD that was 3 SD below the appropriate
control mean. He was 204 cm tall, had an arm span of 213 cm
and eunuchoidal appearance structure, and, due to his open epi-
physes, was still growing slowly during the third decade of his
life. This patient did not respond to high doses of transdermal
ethinyl estradiol (Smith et al., 1994). Laboratory tests revealed
an inactivation mutation in the ERα gene, which led to a sub-
stitution of thymine for cytosine. He was described to have a
normal serum androgen level supporting that the genetic estrogen
resistance indeed was responsible for this skeletal disorder (Smith
et al., 1994). Histomorphometrical analysis of his bones revealed
markedly decreased mineral content and impaired bone structure
although the periosteal circumference was unaffected (Smith et al.,
2008).
A year later, in 1995, a similar phenotype appearance was
described by Morishima and his colleagues. DNA tests revealed
a homozygous mutation of the aromatase P450 (CYP19) gene
that led to high levels of androgens and undetectable levels of
estradiol in the serum (Morishima et al., 1995; Zirilli et al., 2009).
FIGURE 2 | Estrogen receptors (ERs) structures.They contain six domains
(A–F). From the N- to the C-terminus: the A/B domain mediates
transactivation in the absence of ligand (AF-1). The C domain contains the
DNA-binding domain that binds to EREs in target genes. The D domain is a
hinge region that provides ﬂexibility between the C- and N- termini. The E and
F domains contain the site that binds estrogen and estrogenic compounds.
The percentage homology between different domains in these two isoforms
is indicated below these domains.
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In contrast to the ERα-mutated man, this patient responded to
high-dose estrogens.
These case reports indicate that androgen alone is not enough to
advance skeletal maturation and maintain bone mass. Moreover,
they demonstrate that estrogens play an important role in bone
mineralization in both sexes. The expression of ERs in growth
plate chondrocytes of different species (Nilsson et al., 1999, 2002)
suggests that estrogens directly affect growth plate chondrocytes.
ESTROGEN TREATMENT FOR MODULATION OF BONE GROWTH
High-dose estrogen therapy has been documented to effectively
reduce adult height in extremely tall girls (Goldzieher, 1956; Venn
et al., 2008). However, the long-term effects of such treatment
has to be considered. It has been reported that high-dose estro-
gen therapy may reduce fertility later in life (Venn et al., 2004;
Hendriks et al., 2011) and even induce premature ovarian failure
(Hendriks et al., 2011), increase the risk for deep vein thrombo-
sis (Weimann and Brack, 1996), as well as, possibly, increase the
risk for breast and gynecological cancers (Genazzani et al., 2001).
Conversely, inhibition of estrogen biosynthesis by administering
an aromatase inhibitor in patients with idiopathic short stature
successfully delays skeletal maturation and enhances adult height
(Hero et al., 2005). Later, it was reported that such treatment with
an aromatase inhibitor may increase bone resorption (Hero et al.,
2009). Furthermore, 2 years treatment of pre- or early- pubertal
idiopathic short stature males with an aromatase inhibitor led to
vertebral deformities (Hero et al., 2010), again emphasizing the
importance of estrogens for bone health, not only in females but
also in males.
SELECTIVE ESTROGEN RECEPTOR MODULATORS
Unlike estrogens, which are all agonists, and antiestrogens,
which are all antagonists, selective estrogen receptor modulators
(SERMs) include adiversity of compounds that can act as either ER
agonists or antagonists in a tissue-speciﬁc manner (Cho and Nut-
tall, 2001). They dissociate desirable estrogen effects on bone from
undesirable stimulatory effects on the breast and endometrium.
Despite lacking the steroid structure of estrogens, their tertiary
structure allows them to bind to the ERs. Most, of these distinct
activities on target tissues for estrogens can be explained by three
major interacting factors: differences in expression levels of ERα
and ERβ, differences in the conformational changes upon binding
of ligand to ERs, and differences in the expression of coregula-
tor proteins (coactivators or corepressors; Riggs and Hartmann,
2003).
Tamoxifen, a ﬁrst generation SERM, has been used to treat
pubertal gynecomastia in adolescent boys (Derman et al., 2003;
Lawrence et al., 2004) and precocious puberty in patients with
McCune–Albright Syndrome (Eugster et al., 2003). In these stud-
ies, longitudinal growth was either unaffected or diminished fol-
lowing months of treatment (Derman et al., 2003; Eugster et al.,
2003; Lawrence et al., 2004). In an ex vivo model of cultured fetal
ratmetatarsal boneswe earlier reported that tamoxifenmay induce
permanent growth arrest (Chagin et al., 2007). Indeed, in vivo data
in male rats veriﬁed that tamoxifen impairs longitudinal bone
growth, an effect which is accompanied by cortical bone growth
destruction (Karimian et al., 2008).
Raloxifen, another SERM, acts as an estrogen agonist in bone
and as an estrogen antagonist in breast anduterine tissues (Barrett-
Connor, 2001). In rats, this compound inhibits longitudinal bone
growth (Evans et al., 1994) while in ovariectomized rabbits it acts
as an estrogen agonist on the growth plate accelerating chondro-
cyte senescence and thereby hastening epiphyseal fusion (Nilsson
et al., 2003b). In contrast, Zirilli et al. (2009) recently reported
that, unlike in rats and rabbits, raloxifene do not accelerate epi-
physeal fusion, but does enhance BMD and circulating levels of
gonadotropins in aromatase-deﬁcient humans.
CONCLUSION
A better understanding of the genetic regulation of growth plate
cartilage could open for novel therapeutic strategies in children
with different growth disorders. As illustrated in this review, it is
difﬁcult to extrapolate data obtained in experimental animals to
the human growth plate. This emphasizes the urgent need for new
experimentalmodels that will allow studies in human growth plate
cartilage.
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